Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536799 | 0.83 | EGLN3 (0.62) | EGLN3EGLN1 | |
| SCHEMBL3524401 | 0.73 | EGLN3 (0.46) | EGLN3 | |
| SCHEMBL3530106 | 0.73 | CFTR (0.43) | EGLN3CFTR | |
| SCHEMBL3523631 | 0.72 | EGLN3 (0.47) | EGLN3KDM4EKDM4AL3MBTL1ALDH1A1 | |
| SCHEMBL3525718 | 0.71 | EGLN3 (0.44) | EGLN3KDM4ERAB9AEGLN1ALDH1A1 | |
| SCHEMBL3519604 | 0.71 | KDM4E (0.45) | EGLN3KDM4EALDH1A1 | |
| SCHEMBL3520296 | 0.71 | EGLN3 (0.37) | EGLN3KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL3521085 | 0.71 | DPP4 (0.44) | EGLN3KDM4EALDH1A1 | |
| SCHEMBL3567138 | 0.68 | FABP3 (0.42) | EGLN3ALDH1A1 | |
| SCHEMBL3567141 | 0.66 | PTPN1 (0.45) | EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| EP-2227770-A2 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885KDM4E 176/4885CFTR 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.